GSK ’s Shingrix receives approval in Canada to prevent shingles

GlaxoSmithKline ’s (GSK) non-live, recombinant sub-unit, adjuvanted vaccine Shingrix has received approval from Health Canada to prevent shingles (herpes zoster) in people aged 50 or older.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news